NEW YORK (Reuters Health) – An “important” relation exists between platelet reactivity and glycemic control in patients with type 2 diabetes and coronary artery disease who are on dual antiplatelet therapy, researchers report in the November issue of the American Heart Journal.
Dr. Paul A. Gurbel of the Sinai Center for Thrombosis Research in Baltimore, Maryland told Reuters Health, “The more poorly controlled the diabetes, the higher the platelet reactivity. These data suggest a rationale for glycemic control in the diabetic in order to reduce thrombotic risk.”
Dr. Gurbel and his associates compared platelet aggregation in response to 5 and 20
